The overall increase in the chance of uterine cancer with tamoxifen use is lower (fewer than 1%), and it goes again to regular in a number of years of halting the drug. Progression developing six or more months right after initiating the main endocrine therapy for metastatic disorder (either fulvestrant https://jeremyv741jos4.answerblogs.com/profile